⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16671385 | 0.76 | ACE (0.30) | — | |
| Hydrochloric Acid SCHEMBL21798848 | 0.73 | — | — | |
| SCHEMBL30994187 | 0.70 | PREP (0.39) | — | |
| SCHEMBL1846465 | 0.68 | — | — | |
| SCHEMBL30565809 | 0.66 | TSHR (0.34) | — | |
| SCHEMBL29183121 | 0.66 | TSHR (0.34) | — | |
| SCHEMBL28200411 | 0.64 | ACE (0.34) | — | |
| SCHEMBL25435307 | 0.63 | — | — | |
| SCHEMBL17336127 | 0.63 | ACE (0.33) | — | |
| SCHEMBL28856332 | 0.63 | ACE (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240132521-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240002375-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE | REMIX THERAPEUTICS INC. | 2024-01-04 | — | — | US | disclosed |
| WO-2023158221-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | 주식회사 카나프테라퓨틱스 | 2023-08-24 | — | — | WO | disclosed |
| CN-109721620-B | HPK1 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-2260031-A1 | COMPOUNDS THAT ARE ERK INHIBITORS | Schering Corporation (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009105500-A1 | COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |